Safety Alerts & Recalls

Search all Safety Alerts & Recalls

Latest Alerts

Physicians Total Care, Inc Recalls Several Lots of Morphine Sulfate Extended Release and Immediate Release tablet, 30 mg
Physicians Total Care, Inc has recalled several lots of Morphine Sulfate Extended Release and Immediate Release tablets, 30 mg. The following lot numbers have been recalled because the labels have been mixed up and batches of Morphine Sulfate Extended released may have Morphine Sulfate Immediate released tablets and vice-versa: Morphine Sulfate Extended Release tablet, 30 mg, bottles of 60 tablets: Batch number 65IT Morphine Sulfate Immediate Release tablet, 30 mg, bottles of 120 tablets: Batch number 65J2 Morphine Sulfate is used in the treatment of pain. Morphine Sulfate is also sold under other brand names. No other lots, strengths, or brands of Morphine Sulfate were involved in this recall. To view the FDA notice about this recall, please visit: http://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Event-Detail.cfm?action=detail&id=61233&w=06272012
Learn More

King Pharmaceuticals Inc, and Actavis Elizabeth LLC Recall Several Lots of Embeda
King Pharmaceuticals Inc, and Actavis Elizabeth LLC are recalling select lots of Embeda (morphine sulfate and naltrexone hydrochloride) capsules. The following lot numbers are being recalled because samples from these lots failed the routine manufacturer tests that measure the capsules ability to dissolve: 1) Embeda 20 mg/0.8 mg Extended Release Capsules - Lots 581H91, 158G91 and 582H91 2) Embeda 30 mg/1.2 mg Extended Release Capsules - Lots 159G91 and 585H91 3) Embeda 60 mg/2.4 mg Extended Release Capsules - Lots 616H91, 503H91 and 617H91, Exp. 4) Embeda 50 mg/2.0 mg Extended Release Capsules - Lots 160G91, 586H91 and 587H91 5) Embeda 80 mg/3.2 mg Extended Release Capsules - Lot 583H91 6) Embeda 100 mg/4 mg Extended Release Capsules - Lot 588H91 Embeda is used in the treatment of chronic pain and contains the ingredients morphine and naltrexone. This recall alert only applies to these select lots of Embeda. To view the FDA notice about this recall, please visit: http://www.fda.gov/Safety/Recalls/EnforcementReports/ucm214953.htm
Learn More

Date Published Title Drug Source
2012-07-05 Physicians Total Care, Inc Recalls Several Lots of Morphine Sulfate Extended Release and Immediate Release tablet, 30 mg Morphine FDA
2010-06-11 King Pharmaceuticals Inc, and Actavis Elizabeth LLC Recall Several Lots of Embeda Morphine and Naltrexone FDA
2011-03-14 King Pharmaceuticals Inc. Recalls Embeda Morphine and Naltrexone Manufacturer
2008-07-08 Increased risk of tendinitis and tendon rupture Moxifloxacin FDA
2008-08-05 Generic Manufacturer Recalls Several Drug Products Multivitamin Manufacturer
2013-04-26 Saratoga Therapeutics, LLC Recalls ebA Multivitamin Supplement Due to Undeclared Milk Components Multivitamin FDA
2007-11-27 Revised pregnancy rating Mycophenolate FDA
2008-04-10 Potential increased risk of PML Mycophenolate FDA
2008-06-30 Warnings Added To Labeling Mycophenolate Manufacturer
2009-02-13 Medication Guide Available Mycophenolate Manufacturer
2009-07-14 FDA Requires Stronger Warnings on Some Drugs Used to Prevent Rejection of Certain Organ Transplants Mycophenolate FDA
2009-08-14 Cases of Anemia Reported in Patients Treated with CellCept Mycophenolate Manufacturer
2013-01-02 Genentech USA, Inc. Recalls Several Lots of CellCept Capsules, 250 mg Mycophenolate FDA
2009-09-04 Safety Information Added to the Myfortic Prescribing Information Mycophenolic Acid Manufacturer
2012-10-01 FDA Approves REMS Program For Mycophenolate-Containing Medicines to Reduce the Risks for Women Who Can Become Pregnant Mycophenolic Acid FDA
2010-12-02 Johnson and Johnson Recalls Several Mylanta and AlternaGel Liquid Products FDA
2011-06-01 Teva Pharmaceuticals USA Recalls Single Lot of Nabumetone Tablets USP, 750 mg Nabumetone FDA
2008-08-04 Generic Manufacturer Recalls Several Drug Products Naltrexone Manufacturer
2008-08-12 Monitor for Injection Site Reactions Naltrexone FDA
2010-05-04 Medication Guide Reviews Risks of Vivitrol Naltrexone Manufacturer
Back to Consumer Med Safety